Fraud charges filed against diagnostic company
This article was originally published in Clinica
The US Securities and Exchange Commission has brought fraud charges against the now defunct company, Novatek International, reports Barron's, a US business weekly. The company is alleged to have issued false press releases two years ago, claiming it had revenues of $400 million in non-existent transactions, concerning sales of HIV blood test kits in South America.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.